Get the latest updates in your mailbox by subscribing to our newsletter.
UK B1.1.7 SARS-CoV-2 pseudoviruses
**UK B1.1.7 SARS-CoV-2 pseudoviruses available for Neutralization assay: **Preclinics is offering its Customers the Pseudoviral Infection/Neutralization assay with recent mutated strain B1.1.7.
Photo by CDC from Pexels
preclinics is developing assays for SARS-CoV-2 and COVID-19 research. Now our virus neutralizing assays are available to test the neutralizing effect of antibodies and sera. Assays for protease inhibitors, as well as in vivo models in K18-huACE2 mice will follow soon. For covid19 research we have a lung inflammation model established.
COVID-19 Pseudovirus Infection and Neutralisation Service
Preclinics GmbH offers its customers Covid-19 pseudotyped viruses infection and neutralization services in vitro and ex vivo. This service is based on the crucial interaction of trimeric Spike protein of SARS-Cov2 with its eukaryotic counter receptor ACE2.
This service can be used for:
1. Screening patient serum for neutralizing antibodies
2. Validating inhibitors of the Spike-ACE2 interaction
3. COVID-19 vaccine development
**Assay lay out**
preclinics is attending the Immunotherapy for Infectious Diseases Conference 2021 in Streasa at the Lago Maggiore. It is again postponed to later June 2021 and the location will be University of Pavia in Pavia, Italy
For more information please click (link: https://www.idimmunotherapy.com/).